24.85

2.09% -0.53

After Hours: 24.85

Ultragenyx Pharmaceutical Inc (RARE)

Overview News Price History Option Chain Financials Why RARE Down? Discussions Forecast Stock Split

Ultragenyx Pharmaceutical Inc stock is traded at $24.85, with a volume of 2.75M. It is down -2.09% in the last 24 hours and down -0.60% over the past month. Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. The company identifies, acquires, develops, and commercializes novel products for the treatment of serious, rare, and ultra-rare diseases, with a focus on debilitating genetic conditions. Its medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients aged one year and older. Mepsevii is indicated for pediatric and adult patients for the treatment of Mucopolysaccharidosis VII. The company operates across North America, Latin America, Europe, the Middle East and Africa, and Asia-Pacific, with the majority of its revenue generated from North America.

Previous Close:

$25.38

Open:

$25.54

24h Volume:

2.75M

Relative Volume:

1.53

Market Cap:

$2.45B

Revenue:

$669.43M

Net Income/Loss:

$-609.36M

P/E Ratio:

-4.0697

EPS:

-6.1061

Net Cash Flow:

$-507.20M

1W Performance:

+9.04%

1M Performance:

-0.60%

6M Performance:

-27.64%

1Y Performance:

-33.04%

1-Day Range:

$24.51

$25.66

1-Week Range:

$22.43

$25.66

52-Week Range:

$18.29

$42.37

Ultragenyx Pharmaceutical Inc Stock (RARE) Company Profile

Name

Ultragenyx Pharmaceutical Inc

Sector

Healthcare (1107)

Industry

Biotechnology (621)

Phone

415-483-8800

Address

60 LEVERONI COURT, NOVATO, CA

Employee

1,371

Twitter

Next Earnings Date

2026-08-04

Latest SEC Filings

RARE's Discussions on Twitter

Compare RARE vs VRTX, REGN, ARGX, ALNY, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
RARE Ultragenyx Pharmaceutical Inc	24.85	2.50B	669.43M	-609.36M	-507.20M	-6.1061
VRTX Vertex Pharmaceuticals Inc	453.17	114.33B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	614.73	64.47B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	878.49	54.99B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	281.90	38.42B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	156.58	34.03B	742.00K	-1.37B	-1.07B	-7.0731

Ultragenyx Pharmaceutical Inc Stock (RARE) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-24-26	Downgrade	Goldman	Buy → Neutral
Oct-20-25	Initiated	Wells Fargo	Overweight
Jul-28-25	Resumed	H.C. Wainwright	Buy
May-28-25	Initiated	William Blair	Outperform
Jun-06-24	Upgrade	Goldman	Neutral → Buy
Apr-22-24	Initiated	RBC Capital Mkts	Outperform
Dec-08-23	Initiated	Wells Fargo	Overweight
Jun-14-23	Resumed	Credit Suisse	Outperform
Jun-06-23	Upgrade	Evercore ISI	In-line → Outperform
Apr-26-23	Initiated	Cantor Fitzgerald	Overweight
Jan-18-23	Resumed	Canaccord Genuity	Buy
Dec-30-22	Resumed	H.C. Wainwright	Buy
Nov-03-22	Upgrade	Robert W. Baird	Neutral → Outperform
Oct-13-22	Upgrade	Guggenheim	Neutral → Buy
Aug-01-22	Downgrade	Evercore ISI	Outperform → In-line
Mar-16-22	Upgrade	Credit Suisse	Neutral → Outperform
Feb-11-22	Upgrade	JP Morgan	Neutral → Overweight
Sep-30-21	Initiated	H.C. Wainwright	Buy
Aug-19-21	Initiated	UBS	Sell
Jul-15-21	Initiated	Guggenheim	Neutral
Jun-29-21	Upgrade	BofA Securities	Neutral → Buy
Jun-04-21	Resumed	Robert W. Baird	Neutral
May-06-21	Upgrade	Citigroup	Neutral → Buy
May-06-21	Upgrade	Evercore ISI	In-line → Outperform
Apr-26-21	Resumed	Credit Suisse	Neutral
Mar-02-21	Resumed	Stifel	Buy
Feb-12-21	Downgrade	JP Morgan	Overweight → Neutral
Dec-07-20	Downgrade	Wedbush	Outperform → Neutral
Nov-24-20	Resumed	Evercore ISI	In-line
Nov-12-20	Downgrade	BofA Securities	Buy → Neutral
Aug-02-19	Resumed	Wedbush	Outperform
Mar-27-19	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Feb-22-19	Resumed	Raymond James	Outperform
Jan-02-19	Downgrade	Raymond James	Outperform → Mkt Perform
Nov-08-18	Upgrade	Citigroup	Sell → Neutral
Sep-10-18	Initiated	Morgan Stanley	Equal-Weight
Jun-21-18	Downgrade	Credit Suisse	Outperform → Neutral
May-11-18	Upgrade	Barclays	Equal Weight → Overweight
May-10-18	Initiated	Goldman	Neutral
Apr-18-18	Upgrade	SunTrust	Hold → Buy
Mar-22-18	Resumed	Piper Jaffray	Overweight
Feb-21-18	Reiterated	Stifel	Buy
Jan-22-18	Upgrade	Evercore ISI	In-line → Outperform
Jan-18-18	Initiated	Credit Suisse	Outperform
Dec-05-17	Reiterated	Barclays	Equal Weight
Dec-04-17	Upgrade	Jefferies	Hold → Buy
Sep-14-17	Upgrade	Wedbush	Neutral → Outperform

View All

Ultragenyx Pharmaceutical Inc Stock (RARE) Latest News

Jun 15, 2026

Insider Sell Alert: Sanders Corazon (Corsee) D. Sells Shares of Ultragenyx Pharmaceutical Inc (RARE) - GuruFocus

Jun 15, 2026

Ultragenyx EVP sells $46,753 in common stock By Investing.com - Investing.com Australia

Jun 15, 2026

Ultragenyx director Corazon D. Sanders sells $50,100 in stock - Investing.com

Jun 15, 2026

Ultragenyx EVP sells $46,753 in common stock - Investing.com

Jun 15, 2026

Ultragenyx director Corazon D. Sanders sells $50,100 in stock By Investing.com - Investing.com India

Jun 15, 2026

Ultragenyx (RARE) director sells 2,000 shares at $25.05 - Stock Titan

Jun 15, 2026

Ultragenyx (RARE) legal chief sells 1,899 company shares in open market - Stock Titan

Jun 15, 2026

[144] Ultragenyx Pharmaceutical Inc. SEC Filing - Stock Titan

Jun 15, 2026

RARE (NASDAQ) proposed sale of 2,000 restricted shares by broker-dealer - Stock Titan

Jun 15, 2026

Jun 14, 2026

Ultragenyx Pharmaceutical (RARE) Gains 1.5% as Stock Tests Key Resistance Near $25.57Stop Hunt - newsline.com

Jun 14, 2026

Jun 13, 2026

Here is Why Ultragenyx Pharmaceutical (RARE) is One of the Best Buy-the-Dip Stocks - Insider Monkey

Jun 13, 2026

Jun 11, 2026

RARE Stock Edges Up On Priority Review For Gene Therapy In Rare Metabolic Disorder - Stocktwits

Jun 11, 2026